Dennis Ding
Stock Analyst at Jefferies
(2.29)
# 2,639
Out of 5,163 analysts
16
Total ratings
45.45%
Success rate
12.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGP SpyGlass Pharma | Initiates: Buy | $62 | $26.55 | +133.52% | 1 | Mar 3, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.38 | +0.87% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $28.06 | -28.72% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $26.19 | -0.73% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $37.49 | +46.71% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.00 | +300.00% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $28.17 | +24.27% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.26 | +64.32% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $3.42 | +75.44% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $1.32 | +1,793.94% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $32.15 | -31.57% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $28.62 | -16.14% | 1 | Dec 19, 2022 |
SpyGlass Pharma
Mar 3, 2026
Initiates: Buy
Price Target: $62
Current: $26.55
Upside: +133.52%
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.38
Upside: +0.87%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $28.06
Upside: -28.72%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $26.19
Upside: -0.73%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $37.49
Upside: +46.71%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $28.17
Upside: +24.27%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.26
Upside: +64.32%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $3.42
Upside: +75.44%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $1.32
Upside: +1,793.94%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $32.15
Upside: -31.57%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $28.62
Upside: -16.14%